baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer

July 7, 2017
Rita Nanda, MD

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer.